While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
News & Analysis: Acadia Pharmaceuticals
A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.
These drug developers will give your portfolio a boost.
ACAD earnings call for the period ending March 31, 2020.
Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price.
Tumultuous market conditions discounted the stock prices of these leading biotech companies.
ACAD earnings call for the period ending December 31, 2019.
Here are three biotech companies with solid, revenue-driving products to add to portfolios while the price is right.
Acadia Pharmaceuticals and CRISPR Therapeutics both trounced the market last year. Here's why that could continue.
Which biotech was a 37-bagger?